Overview

Study of 5-fluorouracil (5-FU), Nab®1-paclitaxel, Bevacizumab, Leucovorin, and Oxaliplatin in Patients With Metastatic Pancreatic Cancer

Status:
Completed

Trial end date:
2018-10-29

Target enrollment:

Participant gender:

Summary

The purpose of this study is to learn about the safety and potential benefit of metronomic 5-fluorouracil in combination with nab®1-paclitaxel, bevacizumab, leucovorin, and oxaliplatin in treating patients with metastatic pancreatic adenocarcinoma.

Phase:

Phase 1

Details

Lead Sponsor:

Celgene
Celgene Corporation

Treatments:

Albumin-Bound Paclitaxel
Bevacizumab
Calcium
Calcium, Dietary
Fluorouracil
Leucovorin
Levoleucovorin
Oxaliplatin
Paclitaxel